Mutations in the genes encoding hepatocyte nuclear factor 4α (HNF-4α) and HNF-1α impair insulin secretion and cause maturity onset diabetes of the young (MODY). HNF-4α is known to be an essential positive regulator of HNF-1α. More recent data demonstrates that HNF-4α expression is dependent on HNF-1α in mouse pancreatic islets and exocrine cells. This effect is mediated by binding of HNF-1α to a tissue-specific promoter (P2) located 45.6 kb upstream from the previously characterized Hnf4α promoter (P1). Here we report that the expression of HNF-4α in human islets and exocrine cells is primarily mediated by the P2 promoter. Furthermore, we describe a G → A mutation in a conserved nucleotide position of the HNF-1α binding site of the P2 promoter, which cosegregates with MODY. The mutation results in decreased affinity for HNF-1α, and consequently in reduced HNF-1α-dependent activation. These findings provide genetic evidence that HNF-1α serves as an upstream regulator of HNF-4α and interacts directly with the P2 promoter in human pancreatic cells. Furthermore, they indicate that this regulation is essential to maintain normal pancreatic function.
HNF-4α expression remains unaltered in the absence of HNF-1α in liver (11, 13) . This differential regulation is exercised through an alternate tissue-specific HNF-4α promoter (P2) located 45.6 kb upstream of the known promoter (11, 14) . A high-affinity HNF1 binding site in the P2 promoter was shown to bind HNF-1α in vivo in mouse islets (11) , suggesting that HNF-1α regulates the expression of HNF-4α in a direct manner. HNF-1α also controls the expression of multiple other pancreatic transcriptional regulators, such as SHP, HNF-3γ, and HNF-4γ (11, 12) . Interestingly, the HNF-1α dependence of many of these genes is initiated shortly after differentiated cells arise in the pancreas. This observation, together with the fact that HNF-4α and HNF-1α deficiency result in β cell dysfunction (15, 16) , suggests that the tissue-specific regulatory circuit that is controlled by HNF-1α is likely to play a central role in maintaining differentiated pancreatic β cell function. However, because HNF-1α controls the expression of multiple transcriptional regulators and can also directly interact with its distal targets, the notion that HNF-4α is an essential downstream effector of HNF-1α in β cells has not been demonstrated. Moreover, evidence that this regulatory circuit operates in vivo in human cells is lacking.
Earlier studies have shown that a mutated binding site for the IPF-1 transcription factor in the P2 promoter of the HNF-4α gene cosegregates with diabetes (17) . In this study we have identified a loss-of-function mutation in the HNF-1α binding site of the human HNF-4α P2 promoter that causes diabetes in a large family diagnosed with MODY. Our finding provides genetic evidence for the role of HNF-1α as a major regulator of HNF-4α expression in the human pancreas, and proves for the first time that the regulatory action of HNF-1α on the HNF-4α gene is crucial for the function of pancreatic cells.
Methods

MODY family.
A Czech MODY family with autosomal dominant inherited diabetes and three family members with onset of diabetes before the age of 25 years were studied (see Figure 2 ). Using denaturing HPLC and direct sequencing as described previously (18-21), we excluded mutations in the known exons or promoter regions of the HNF-4α, GCK, HNF-1α, IPF-1, and NeuroD1 genes. Subsequently, a linkage study was done using fluorescently labeled polymorphic microsatellite markers flanking genes previously shown to be associated with MODY. Markers were chosen from the ABI PRISM linkage mapping set, version 2 (Applied Biosystems, Torrance, California, USA), and from GeneMap99 (National Center for Biotechnology Information; www.ncbi.nlm.nih.gov/genemap99). Markers used were as follows. For the HNF-4α gene on chromosome 20: D20S96, ADA, D20S119, D20S17, and D20S197. For the GCK gene on chromosome 7: D7S667, GCK1, GCK2, D7S519, and D7S2506. For the HNF-1α gene on chromosome 12: D12S321, D12S807, and D12S342. For the IPF-1 gene on chromosome 13: D13S221, D13S1254, and D13S289. For the HNF-1β gene on chromosome 17: D17S927, D17S1788, and D17S800. For the NeuroD1 gene on chromosome 2: D2S335, D2S364, and D2S2188. The PCR products were loaded on an ABI 377 sequencer (Applied Biosystems) and analyzed using GeneScan 3.1 and Genotyper 2.0 software (Applied Biosystems). The multipoint linkage calculations were performed using the computer program LINKMAP in the FASTLINK package (ftp://fastlink.nih.gov/pub/fastlink/) (22) . Four different liability classes were used for healthy carriers. Healthy carriers between 0 and 10 years of age have a 48% risk of being affected; between 10 and 25 years of age the risk is 25%; between 25-40 years of age there is a 10% risk of being affected; and healthy persons above 40 year of age have a 2% risk of being affected.
In the nondiabetic children (ID nos. 142, 145, 146, 149, and 150 in Figure 2 ), we performed an intravenous glucose tolerance test with injection of 50% glucose (0.3 g per kg body weight) after an overnight fast. Blood samples were drawn before glucose injection and at 2, 4, and 8 minutes after injection for analysis of serum insulin. Glucose-induced acute-phase serum insulin response was calculated as the area under the curve from 0 to 8 minutes as described (23) . Serum insulin was determined by ELISA as described (24) . Informed consent was obtained from all studied subjects prior to their participation in the study. The study was approved by the Ethical Committee of the Third Faculty of Medicine at Charles University and was carried out in accordance with the principles of the Declaration of Helsinki II.
Sequence analysis. Primers used to amplify the P2 promoter region and exon 1D were designed from human genomic clone AL117382.28 using Primer3 software (http://www-genome.wi.mit.edu/genome_software/ other/primer3.html) (25) . PCR amplification was carried out as described earlier (26) . The PCR products were then sequenced using a BigDye Terminator cycle sequencing kit and analyzed on an ABI PRISM 377 automated sequencer (Applied Biosystems). After detection of the mutation in the proband, DNA from all family members was sequenced using primers 6F (5′-TGATGTCCCCATACACCTG-3′) and 6R (5′-GATTCTTC-
RNA expression analysis. First-strand cDNA was prepared with Superscript II (Life Technologies Inc., Gaithersburg, Maryland, USA) using random hexamers (Promega Corp., Madison, Wisconsin, USA) on total RNA from human liver (Clontech Laboratories Inc., Palo Alto, California, USA) or gradient-enriched pancreatic islet and exocrine tissue (27) . Primers were designed to amplify HNF-4α exons 1D to 2 (1DF-2Ra), 1A to 2 (1AF-2Rb), 8 to 10 (8F-10R), 8 (8F-8R), and β-actin (ACTF-ACTR) ( Figure 1a ). Oligonucleotide sequences were as follows. 1DF: 5′-GCGGGCCCCTGCTCCTC-CAT-3′; 2Ra: 5′-AGAAGCCCTTGCAGCCGTCACAG-3′; 1AF: 5′-ACATGGACATGGCCGACTAC-3′; 2Rb: 5′-CTCGAGG-CACCGTAGTGTTT-3′; 8F: 5′-AAGATCAAGCGGCTGC-GTTCC-3′; 10R: 5′-CTGGCGGTGAGGGCTGTGG-3′; 8R: 5′-ACTCCAACCCCGCCCCTCCTG-3′; ACTF: 5′-CAAGGC-CAACCGCGAGAAGATG-3′; ACTR: 5′-CTGGCCAGCCAG-GTCCAGA-3′. PCR was carried out under standard conditions with limited cycle numbers, and products were analyzed in ethidium bromide-stained nondenaturing acrylamide gels.
Electromobility shift assays. Electromobility shift assays (EMSAs) were carried out with synthetic HNF-1α prepared by in vitro transcription/translation, as described previously (11) . Sequences of the doublestranded oligonucleotides are shown in Figure 3a . Quantification was performed with Molecular Imager FX (Bio-Rad Laboratories Inc., Hercules, California, USA) and Scion Image software (Scion Corp., Frederick, Maryland, USA). Competition curves were analyzed with GraphPad Prism (GraphPad Software, San Diego, California, USA).
Plasmids. P2 promoter fragments comprising positions -371 to -37 or -171 to -37 relative to the initiator codon were generated by PCR and inserted into pGL2-Basic (Promega Corp.) to generate P2.371 and P2.171. The mutations described above for EMSA studies were introduced into the P2.371 vector generating P2.371/HNF1G→A and P2.371/HNF1→SAC plasmids and were verified by sequencing.
Transient transfection assays. Human colon CaCo2 cells, mouse 10T/2 fibroblasts, and mouse MIN6 β cells were trypsinized 14 hours before transfection, distributed into 12-well plates (3 × 10 4 cells/well) and maintained in DMEM supplemented with 15% FBS. Cells were transfected with 400 ng P2 promoter plasmids using Effectene (Qiagen Inc., Valencia, California, USA). pCMV-β-galactosidase (1 ng) was added to control for transfection efficiency.
For stimulation experiments, 0, 0.05, 0.5, 5, or 10 ng pBJ5-HNF1α was added in the presence or absence of 50 ng pBJ5-DCoH. Fixed amounts of DNA were maintained with empty pBJ5 vector. After 48 hours of incubation, luciferase and β-galactosidase were measured with chemiluminescent assays (Roche Diagnostics Corp., Indianapolis, Indiana, USA). At least three independent experiments were performed, each of which tested two to three independent clones for each reporter plasmid construction in duplicate. For each well, luciferase/galactosidase activity was calculated and expressed as a percentage of average luciferase/ galactosidase activity values measured with P2.371 alone or P2.371 plus empty pBJ5 plasmids in the same experiment. Differences between means were assessed by Student t test.
Results
Expression of HNF-4α transcripts in human pancreas.
In order to elucidate HNF-4α promoter usage in human pancreatic tissue, primers were designed to selectively amplify exon 1D or exon 1A (corresponding to HNF-4α isoforms driven by the P2 and P1 promoters, respectively) ( Figure  1a ). Our results show that P2 is the predominant promoter driving HNF-4α expression in human islets and exocrine pancreatic cells, while in human liver cells, HNF-4α expression is primarily directed by the P1 promoter, and to a much lesser degree by P2 (Figure 1b) . Further analysis revealed that all three known 3′ HNF-4α splice variations are expressed in human pancreatic islets ( Figure 1, a and c) . Because these HNF-4α transcripts contain exon 1D rather than 1A, we refer to these three isoforms as HNF-4α7, HNF-4α8, and HNF-4α9 Identification of a mutation in the HNF-1α binding site of the P2 promoter. We sequenced 1 kb of the P2 promoter, exon 1D, and the exon/intron boundary in the proband from the MODY1 locus-linked family (Figure 2 ) without known mutations in the previously published sequences of the HNF-4α gene. The results revealed a G → A nucleotide substitution at position -181 from the translation start site, which is positioned in the previously described HNF-1α binding site (11, 14) .
Genotyping of all family members revealed evidence of cosegregation of this mutation and diabetes in the family (Figure 2 ). Notice that subject 141 has diabetes but is a wild-type carrier. However, diabetes was diagnosed at the age of 70, and therefore it is plausible that he has a common form of late-onset type 2 diabetes and not MODY. Furthermore, as the deceased spouse of 141 is a monozygotic twin to 151, she is an obligate carrier of the mutation, and thus the mutation was inherited from this deceased spouse rather than from subject 141. Finally, the mutation was not found in 90 normal Czech chromosomes, or in more than 200 normal Danish chromosomes.
Examination of β cell function. Subjects 142 and 145 are heterozygous carriers, but are normal glucose tolerant. These subjects are 16 and 8 years old, respectively, and it is likely that they are too young to have developed a diabetic phenotype. We therefore examined their β cell function with an intravenous glucose tolerance test in order to test for a possible early β cell defect. Both mutation carriers have a relatively low insulin secretion capacity compared with the control population. Subjects 142 and 145 had a fasting serum insulin of 16 pmol/l and 11 pmol/l, respectively (reference interval obtained from data from 380 young Danes, median [10-90% percentiles]; 31 pmol/l, [17-66 pmol/l]). For comparison, subjects 146, 149, and 150 had fasting serum insulin concentrations of 49 pmol/l, 8 pmol/l, and 34 pmol/l. Estimation of the glucose-induced acute-phase serum insulin response for the first 8 minutes after an intravenous glucose load for subjects 142 and 145 was 1,154 min × pmol/l and 1,377 min × pmol/l, respectively; for subjects 146, 149, and 150, estimations were 5,043 min × pmol/l, 893 min × pmol/l, and 2,258 min × pmol/l, respectively (reference interval 2,252 min × pmol/l [1,078-4,457 min × pmol/l]). Furthermore, the majority of the diabetic subjects from the family are treated with insulin, indicating that, as expected, the mutation is associated with β cell insufficiency.
Functional analysis of the -181G→A mutation. Oligonucleotide competition assays were carried out to evaluate the impact of the -181G→A mutation on the affinity for HNF-1α. As shown in Figure 3 , b and c, an amount of unlabeled HNF1G→A oligonucleotide sevenfold higher than the amount of wild-type oligonucleotide was required for half-maximal inhibition of binding of HNF-1α to its cognate site. For comparison, an artificially designed 4-bp substitution mutation (oligonucleotide HNF1→SAC) that modifies highly conserved nucleotides in the HNF1 site (29) completely disrupted sequence-specific binding.
The significance of these DNA-binding modifications on P2 promoter activity was assessed in 10T/2 fibroblasts, which do not express HNF-1α. Cells were transfected with increasing concentrations of pBJ5-HNF1α plus the luciferase reporter plasmid constructions shown in the schematic in Figure 4a . Figure 4b shows that HNF-1α stimulates the wild-type promoter (P2.371), but not a similar plasmid carrying the HNF1→SAC mutation. In keeping with the fact that the HNF1G→A mutation retains the ability to bind HNF-1α with reduced affinity, P2.371/ HNF1G→A can
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The be stimulated by HNF-1α, although higher concentrations of HNF-1α expression plasmid are required for half-maximal stimulation (ED 50 for P2.371/HNF1G→A, 2 ± 0.4 vs. P2.371, 0.9 ± 0.4 ng), and maximal stimulation is significantly reduced (Figure 4b ). Transactivation by HNF-1α of wild-type and P2.371/HNF1G→A promoters is specific, as it is potentiated by the dimerization cofactor of HNF-1α, DCoH, which does not elicit stimulation of the P2.371/HNF1→SAC-null mutant plasmid (Figure 4c ) or of the P2.171 deletion plasmid lacking the HNF-1α binding site (not shown).
We then studied the intrinsic activity of P2 promoter plasmids in cells with endogenously expressed HNF-1α and HNF-4α exon 1D. In both MIN6 β cells and CaCo2 intestinal cells, P2.171, P2.371/HNF1G→A, and P2.371/HNF1→SAC plasmids had similarly reduced activity compared with the P2.371 wild-type plasmid (Figure 4d ). These results suggest that under physiological activator concentrations, the reduction in the affinity for HNF-1α caused by the HNF1G→A mutation is sufficient to disrupt HNF-1α-dependent activation of the P2 promoter.
Discussion
Very recent studies have uncovered an alternate promoter of the mouse and human genes encoding HNF-4α (11, 14) . This promoter, named P2, contains an HNF1 consensus element that is occupied in vivo by HNF-1α in mouse islets (11) . Its transcriptional activity becomes dependent on HNF-1α as pancreatic endocrine and exocrine cells initiate terminal differentiation during mouse embryonic development (11) . This suggests that HNF-4α may be a critical mediator of the function of HNF-1α in a genetic program destined to control differentiated pancreatic β cell function. However, the relative importance of HNF-4α as a downstream effector of HNF-1α cannot be concluded from those studies, as HNF-1α also controls the expression of multiple other transcriptional regulators (11, 12) . Furthermore, previous studies did not establish whether HNF-1α acts on the P2 promoter through a single or multiple HNF1 sites, or whether intermediary HNF-1α-dependent transcriptional regulators are critically involved in the requirement for HNF-1α to control this promoter. In addition, formal evidence that the P2 promoter is the major HNF-4α transcription initiation site and that HNF-1α is necessary for HNF-4α expression in human pancreatic cells is lacking.
The present study provides evidence to address these issues. Using RT-PCR we demonstrate that the major HNF-4α isoforms in human exocrine and endocrine pancreas are transcribed from the P2 promoter. Although pure human β cells are not available to verify that the alternative HNF-4α isoform is present in this particular islet cell type in humans, previous studies using mouse MIN6 β cell lines indicate that HNF-4α exon 1D is indeed expressed in insulin-producing cells (30) . Furthermore, we have identified a single nucleotide -181G→Α mutation in the HNF-1α binding site of the P2 promoter of HNF-4α that cosegregates with diabetes in a large MODY pedigree. Several factors suggest that the identified mutation causes diabetes in the family. First, multipoint linkage studies revealed a suggestive linkage to the HNF-4α region on chromosome 20, whereas all other known MODY loci were excluded by linkage and/or direct mutation screening. Second, the mutation is not present in nearly 300 control chromosomes. Third, the low fasting insulin levels and the relative impaired insulin response to intravenous glucose in healthy mutation carriers indicate that the mutation causes an early β cell defect as also previously reported in MODY1 subjects (31) . Also, we performed an oral glucose tolerance test in the diabetic subject cz147 that revealed low serum insulin levels at all time points during the test compared with subjects having type 2 diabetes (data not shown). These observations point to a progressive β cell defect. Obviously however, prospective data are needed to illuminate the natural fate of the β cell function in mutation carriers. Fourth, the mutation results in reduced in vitro binding of HNF-1α to its cognate site and impairs HNF-1α-dependent transcriptional activation. The results indicate that the diabetic phenotype of -181G→A mutation carriers is caused by the decreased expression of HNF-4α as a consequence of a disruption of HNF-1α-dependent activation of the P2 promoter. While it is also possible that the mutation disrupts regulation by HNF-1β, which in vitro possesses a DNAbinding sequence specificity almost identical to that of HNF-1α, there is currently insufficient evidence that HNF-1β is important for P2 promoter activity in adult pancreas, as HNF-4α expression is severely impaired in hnf-1α-null mice in the presence of normal levels of HNF-1β (11, 12) . Thus, these results represent the first in vivo indication that HNF-1α is required for HNF-4α expression in humans.
The observation that the disruption of a single cis element is linked and associated with diabetes provides important novel information concerning the mechanism whereby HNF-1α controls HNF-4α expression. It shows that the essential role of HNF-1α in the P2 promoter can be narrowed down to a direct interaction with a single cis element. Furthermore, while defective expression of multiple transcriptional regulators has been documented in hnf-1α-deficient pancreatic cells (11, 12) , the -181G→Α mutation shows that HNF-1α deficiency per se (rather than the loss of intermediary factors) underlies the HNF-1α dependence of the P2 promoter.
It is currently not established whether decreased expression of HNF-4α in HNF-1α deficiency is relevant to the mechanism of β cell dysfunction. For example, β cell dysfunction resulting from primary HNF-4α deficiency (e.g., in MODY1) could theoretically be exclusively mediated through the resulting HNF-1α deficiency, while the phenotype in hnf-1α-null mutant mice could primarily result from the direct effects of HNF-1α on its distal targets, as well as from defective expression of other intermediary transcriptional regulators. The -181G→A mutation provides for the first time proof that HNF-1α control of the HNF-4α P2 promoter is on its own essential for β cells to function normally. Thus, despite the apparent complexity of the transcriptional regulatory circuit in which this interaction is immersed (7, 11, 12) , this mutation reveals a discrete regulatory site that is indispensable to its function. It is hypothesized that modulators of the HNF-4α P2 promoter, or more specifically modulators of HNF-1α action on this promoter, may be of importance to control the differentiation or function of human pancreatic β cells.
The genetic and RT-PCR findings described here also confirm the essential role of the P2 promoter in the expression of HNF-4α in human pancreatic cells. This is consistent with a recent report by Thomas et al.
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The describing a loss-of-function mutation located in a TAAT element in the HNF-4α P2 promoter that binds recombinant PDX-1 (14) . This mutation cosegregates with diabetes in a large British MODY family. Obviously, these findings should stimulate further studies of MODY families of unexplained genetic background to estimate the prevalence of MODY due to variability in exon 1D and the P2 promoter. Furthermore, they warrant an assessment of the possible role of genetic variability in this promoter region in the pathogenesis of type 2 diabetes, as several studies have demonstrated linkage to chromosome 20q12-q13.1 (32) .
In conclusion, the current study indicates that HNF-1α is a major regulator of HNF-4α expression in the human pancreas, acting directly through a distinct essential cis element in the HNF-4α P2 promoter. Together with previous human and rodent studies indicating that HNF-4α controls the expression of HNF-1α, this finding provides independent evidence for the existence of a positive cross-regulatory loop between HNF-1α and HNF-4α in human pancreatic cells (9, 11, 12, 33, 34) ( Figure 5 ). Furthermore, it proves that despite the complexity of the pancreatic HNF-1α-dependent regulatory network (11, 12) , the interaction between HNF-1α and the HNF-4α P2 promoter is indispensable for human pancreatic β cell function.
